Biological and Clinical Manifestations of Huntington’s disease in Gene Carriers Very Far from Predicted Onset: The Young Adult Study
Objective: To perform a deep phenotyping of a Huntington’s Disease (HD) cohort further from onset than previously studied to establish when disease related markers first…A Rare Disease with Atypical Clinical And Imaging Findings: Anti Lgi-1 Encephalitis
Objective: We present a case that will raise awareness about the disease with atypical clinical and rich imaging findings that has benefited greatly from intensive…Hyperpolarization of the subthalamic nucleus alleviates hyperkinetic movement disorders
Objective: We test the hypothesis of modulating subthalamic neuronal firing pattern via injection of hyperpolarizing current as an effective treatment for hyperkinetic movement disorders. Background:…Real-World Deutetrabenazine Dosing Patterns in Patients With Huntington’s Disease or Tardive Dyskinesia
Objective: To evaluate real-world treatment patterns and adherence to deutetrabenazine (DTBZ) in patients with Huntington’s disease (HD) or tardive dyskinesia (TD). Background: DTBZ is a…Huntington’s disease in Egypt; A big challenge for a mysterious disease
Objective: To identify the challenges of managing Huntington’s disease in Egypt in order to overcome them. Background: Huntington’s disease (HD) is considered a rare disease…Healthcare resource utilisation and costs among patients with versus without Huntington’s disease in the US population
Objective: Compare the marginal healthcare resource utilisation (HRU) and costs between US patients with Huntington’s disease (HD) and non-HD controls. Background: HD is a genetic,…Deutetrabenazine for Huntington’s disease chorea—A Single Center’s Experience
Objective: To evaluate real-world use and outcomes with deutetrabenazine for Huntington’s disease. Background: Grade A evidence for Huntington’s disease chorea treatment includes tetrabenazine and deutetrabenazine.…Evaluation of the Safety of Deutetrabenazine at Higher Doses to Treat Chorea in Huntington’s Disease
Objective: To evaluate the safety and tolerability of deutetrabenazine >48 mg/d compared to ≤48 mg/d to treat Huntington’s disease (HD)–associated chorea in ARC-HD. Background: In…VMAT 2 inhibitor and Antipsychotic use in Individuals with Huntington’s Disease
Objective: To retrospectively investigate whether the concomitant use of VMAT2 inhibitors and antipsychotics in individuals with Huntington's disease (HD) is associated with an increased occurrence…MRI, Clinical, and Neuropathological Findings after Bilateral Intra-striatal Administration of rAAV5-miHTT in Non-human Primates
Objective: To assess the effects of intra-striatal administration of a huntingtin protein (HTT) lowering gene therapy in macaca fascicularis non-human primates (NHP). Background: The aggregation…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- 11
- Next Page »